William J. Burman

TL;DR: Episodic antiretroviral therapy guided by the CD4+ count significantly increased the risk of opportunistic disease or death from any cause, as compared with continuous antireteviral therapy, largely as a consequence of lowering theCD4+ cell count and increasing the viral load.

TL;DR: Knowledge of class-specific adherence–resistance relationships may help clinicians and patients tailor therapy to match individual patterns of adherence in order to minimize the development of resistance at failure and guide the selection of optimal drug combinations and regimen sequences to improve the durability of antiretroviral therapy.

TL;DR: Intermittent rifabutin-based therapy for HIV-related TB was well tolerated, but there was a high risk of treatment failure or relapse with acquired rifamycin resistance among patients with low CD4 lymphocyte counts.

TL;DR: Differential adherence was commonly reported and was associated with an increased risk of initial virological failure and initial virology failure with antiretroviral resistance.

TL;DR: The effect of rifampin and the human multidrug resistance gene (MDR1) C3435T polymorphisms (P-glycoprotein) on moxifloxacin pharmacokinetic parameters was evaluated and it was concluded that the interaction between the two drugs and the MDR1 polymorphisms is likely to have clinical significance.